New insider activity at Edwards Lifesciences ( (EW) ) has taken place on May 22, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CVP, TMTT & Surgical executive Daveen Chopra has recently reduced his stake in Edwards Lifesciences, selling 1,500 shares of company stock in a transaction valued at $126,900. This insider sale highlights a notable move by a key leader within the organization and may draw attention from investors tracking executive trading activity at Edwards Lifesciences.
Spark’s Take on EW Stock
According to Spark, TipRanks’ AI Analyst, EW is a Outperform.
The score is driven by strong underlying fundamentals (high margins and very low leverage) and a constructive earnings-call outlook with confident 2026 growth and margin expansion expectations. These strengths are tempered by weak technical positioning (below major moving averages) and a premium valuation (P/E ~30.5) without a dividend yield.
To see Spark’s full report on EW stock, click here.
More about Edwards Lifesciences
YTD Price Performance: -2.40%
Average Trading Volume: 4,917,154
Technical Sentiment Signal: Strong Buy
Current Market Cap: $47.77B